Cargando…

Exploration of a potent PI3 kinase/mTOR inhibitor as a novel anti-fibrotic agent in IPF

RATIONALE: Idiopathic pulmonary fibrosis (IPF) is the most rapidly progressive and fatal of all fibrotic conditions with no curative therapies. Common pathomechanisms between IPF and cancer are increasingly recognised, including dysfunctional pan-PI3 kinase (PI3K) signalling as a driver of aberrant...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mercer, Paul F, Woodcock, Hannah V, Eley, Jessica D, Platé, Manuela, Sulikowski, Michal G, Durrenberger, Pascal F, Franklin, Linda, Nanthakumar, Carmel B, Man, Yim, Genovese, Federica, McAnulty, Robin J, Yang, Shuying, Maher, Toby M, Nicholson, Andrew G, Blanchard, Andy D, Marshall, Richard P, Lukey, Pauline T, Chambers, Rachel C
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2016
Materias:	Interstitial Lung Disease
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4975851/ https://www.ncbi.nlm.nih.gov/pubmed/27103349 http://dx.doi.org/10.1136/thoraxjnl-2015-207429

Ejemplares similares

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA(1)) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)
por: Corte, Tamera J, et al.
Publicado: (2021)

Investigating the effects of nintedanib on biomarkers of extracellular matrix turnover in patients with IPF: design of the randomised placebo-controlled INMARK®trial
por: Maher, Toby M, et al.
Publicado: (2018)

Readily accessible CT scoring method to quantify fibrosis in IPF
por: Fraser, Emily, et al.
Publicado: (2020)

Time to diagnosis of idiopathic pulmonary fibrosis in the IPF-PRO Registry
por: Snyder, Laurie D, et al.
Publicado: (2020)

Rationale for and design of the Idiopathic Pulmonary Fibrosis–PRospective Outcomes (IPF-PRO) registry
por: O'Brien, Emily C, et al.
Publicado: (2016)

Interpretation of HRCT Scans in the Diagnosis of IPF: Improving Communication Between Pulmonologists and Radiologists
por: Chung, Jonathan H., et al.
Publicado: (2018)

Survival and acute exacerbation for patients with idiopathic pulmonary fibrosis (IPF) or non-IPF idiopathic interstitial pneumonias: 5-year follow-up analysis of a prospective multi-institutional patient registry
por: Tsubouchi, Kazuya, et al.
Publicado: (2023)

Diagnostic delay in IPF impacts progression-free survival, quality of life and hospitalisation rates
por: Hoyer, Nils, et al.
Publicado: (2022)

ILD-specific health-related quality of life in systemic sclerosis-associated ILD compared with IPF
por: Durheim, Michael T, et al.
Publicado: (2020)

Monocyte and neutrophil levels are potentially linked to progression to IPF for patients with indeterminate UIP CT pattern
por: Achaiah, Andrew, et al.
Publicado: (2021)

PGC1α repression in IPF fibroblasts drives a pathologic metabolic, secretory and fibrogenic state
por: Caporarello, Nunzia, et al.
Publicado: (2019)

Neutrophil levels correlate with quantitative extent and progression of fibrosis in IPF: results of a single-centre cohort study
por: Achaiah, Andrew, et al.
Publicado: (2023)

Investigating significant health trends in idiopathic pulmonary fibrosis (INSIGHTS-IPF): rationale, aims and design of a nationwide prospective registry
por: Behr, Juergen, et al.
Publicado: (2014)

Cross-Atlantic modification and validation of the A Tool to Assess Quality of Life in Idiopathic Pulmonary Fibrosis (ATAQ-IPF-cA)
por: Yorke, Janelle, et al.
Publicado: (2014)

Randomised clinical trial of an early palliative care intervention (SUPPORT) for patients with idiopathic pulmonary fibrosis (IPF) and their caregivers: protocol and key design considerations
por: Lindell, Kathleen Oare, et al.
Publicado: (2018)

Inhibition of mast cells: a novel mechanism by which nintedanib may elicit anti-fibrotic effects
por: Overed-Sayer, Catherine, et al.
Publicado: (2020)

Use of peripheral neutrophil to lymphocyte ratio and peripheral monocyte levels to predict survival in fibrotic hypersensitivity pneumonitis (fHP): a multicentre retrospective cohort study
por: Barratt, Shaney L, et al.
Publicado: (2021)

Effect of statins on disease-related outcomes in patients with idiopathic pulmonary fibrosis
por: Kreuter, Michael, et al.
Publicado: (2017)

Nintedanib in patients with idiopathic pulmonary fibrosis and preserved lung volume
por: Kolb, Martin, et al.
Publicado: (2017)

Sarcoidosis in the UK: insights from British Thoracic Society registry data
por: Thillai, Muhunthan, et al.
Publicado: (2019)

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: design of a double-blind, randomised, placebo-controlled phase II trial
por: Maher, Toby M, et al.
Publicado: (2018)

The King’s Brief Interstitial Lung Disease (KBILD) questionnaire: an updated minimal clinically important difference
por: Sinha, Aish, et al.
Publicado: (2019)

Rationale, design and objectives of two phase III, randomised, placebo-controlled studies of GLPG1690, a novel autotaxin inhibitor, in idiopathic pulmonary fibrosis (ISABELA 1 and 2)
por: Maher, Toby M, et al.
Publicado: (2019)

Deficiency of tumour necrosis factor-related apoptosis-inducing ligand exacerbates lung injury and fibrosis
por: McGrath, Emmet E, et al.
Publicado: (2012)

Design of a phase III, double-blind, randomised, placebo-controlled trial of BI 1015550 in patients with progressive pulmonary fibrosis (FIBRONEER-ILD)
por: Maher, Toby M, et al.
Publicado: (2023)

Cluster analysis of transcriptomic datasets to identify endotypes of idiopathic pulmonary fibrosis
por: Kraven, Luke M, et al.
Publicado: (2023)

Understanding the burden of interstitial lung disease post-COVID-19: the UK Interstitial Lung Disease-Long COVID Study (UKILD-Long COVID)
por: Wild, Jim M, et al.
Publicado: (2021)

Specialist palliative care, psychology, interstitial lung disease (ILD) multidisciplinary team meeting: a novel model to address palliative care needs
por: Barratt, Shaney L, et al.
Publicado: (2018)

Analytic Morphomics in Myositis-Related Interstitial Lung Disease
por: O’Mahony, Alexander T., et al.
Publicado: (2023)

TELO-SCOPE study: a randomised, double-blind, placebo-controlled, phase 2 trial of danazol for short telomere related pulmonary fibrosis
por: Mackintosh, John A, et al.
Publicado: (2021)

A qualitative study of informal caregivers’ perspectives on the effects of idiopathic pulmonary fibrosis
por: Belkin, Amanda, et al.
Publicado: (2014)

Connective tissue disease related interstitial lung diseases and idiopathic pulmonary fibrosis: provisional core sets of domains and instruments for use in clinical trials
por: Saketkoo, Lesley Ann, et al.
Publicado: (2014)

Combined pulmonary fibrosis and emphysema: effect of pulmonary rehabilitation in comparison with chronic obstructive pulmonary disease
por: Tomioka, Hiromi, et al.
Publicado: (2016)

Safety of pirfenidone in patients with idiopathic pulmonary fibrosis: integrated analysis of cumulative data from 5 clinical trials
por: Lancaster, Lisa, et al.
Publicado: (2016)

Sequencing of idiopathic pulmonary fibrosis-related genes reveals independent single gene associations
por: Coghlan, Meghan A, et al.
Publicado: (2014)

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis
por: Nathan, Steven D, et al.
Publicado: (2016)

Antineutrophil cytoplasmic antibody-positive conversion and microscopic polyangiitis development in patients with idiopathic pulmonary fibrosis
por: Kagiyama, Naho, et al.
Publicado: (2015)

Mindfulness-based stress reduction in patients with interstitial lung diseases: a pilot, single-centre observational study on safety and efficacy
por: Sgalla, Giacomo, et al.
Publicado: (2015)

Lymphangiogenic factors are associated with the severity of hypersensitivity pneumonitis
por: Yamashita, Masahiro, et al.
Publicado: (2015)

Yield of EBUS-TBNA for the diagnosis of sarcoidosis: impact of operator and cytopathologist experience
por: Navasakulpong, Asma, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_lrpcqbrrqj2vccsal7jucvic2s